![European Crohn´s and Colitis Organisation - ECCO - P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase European Crohn´s and Colitis Organisation - ECCO - P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC22/abstracts/0000000370/0000889480/Images/Figure3110821.png)
European Crohn´s and Colitis Organisation - ECCO - P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase
![European Crohn´s and Colitis Organisation - ECCO - P293 Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe European Crohn´s and Colitis Organisation - ECCO - P293 Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC22/abstracts/0000000370/0000043280/Images/Figure4.jpg)
European Crohn´s and Colitis Organisation - ECCO - P293 Insights from patients with Ulcerative Colitis on disease burden: Findings from a real-world survey in Europe
![Main initiatives by medical societies and health-related organisations | Download Scientific Diagram Main initiatives by medical societies and health-related organisations | Download Scientific Diagram](https://www.researchgate.net/profile/Lydia-Makaroff/publication/348924952/figure/tbl1/AS:986199493726209@1612139690321/Main-initiatives-by-medical-societies-and-health-related-organisations.png)
Main initiatives by medical societies and health-related organisations | Download Scientific Diagram
![2017 European Ulcerative Colitis Guidelines - Diagnosis - Part One of Two Parts - Page 6 of 11 - Tom Wade MD 2017 European Ulcerative Colitis Guidelines - Diagnosis - Part One of Two Parts - Page 6 of 11 - Tom Wade MD](https://www.tomwademd.net/wp-content/uploads/2017/12/fig4-4.png)
2017 European Ulcerative Colitis Guidelines - Diagnosis - Part One of Two Parts - Page 6 of 11 - Tom Wade MD
![European Crohn´s and Colitis Organisation - ECCO - P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase European Crohn´s and Colitis Organisation - ECCO - P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC22/abstracts/0000000370/0000889480/Images/Figure2110821.png)
European Crohn´s and Colitis Organisation - ECCO - P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase
![PDF) 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management PDF) 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management](https://i1.rgstatic.net/publication/313399984_3rd_European_Evidence-based_Consensus_on_the_Diagnosis_and_Management_of_Crohn's_Disease_2016_Part_1_Diagnosis_and_Medical_Management/links/5fed788fa6fdccdcb81b0bd8/largepreview.png)
PDF) 3rd European Evidence-based Consensus on the Diagnosis and Management of Crohn's Disease 2016: Part 1: Diagnosis and Medical Management
![European Crohn´s and Colitis Organisation - ECCO - P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase European Crohn´s and Colitis Organisation - ECCO - P370 Maintenance of health-related quality of life improvements with upadacitinib treatment among patients with moderately to severely active ulcerative colitis: results from 52-week phase](https://cm.ecco-ibd.eu/cmAbstractSubmission/Content/cmabstsms/EC22/abstracts/0000000370/0000889480/Images/Figure1110821.png)